Status | Study |
Not yet recruiting |
Study Name: Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies Condition: Hemophilia Date: 2017-05-16 Interventions: Other: Non interventionnal study A query form to all concerned patients by each investigating centre wil |
Available |
Study Name: An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors Condition: Hemophilia A Date: 2017-05-12 Interventions: Biological: Emicizumab Participants will receive emicizumab at a loading dose of 3 milligrams per kilogr |
Not yet recruiting |
Study Name: DDAVP vs. Exercise Condition: Children With Mild Hemophilia A Date: 2017-04-27 Interventions: Drug: DDAVP intervention For t |
Not yet recruiting |
Study Name: Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies Condition: Hemophilia A Date: 2017-03-31 Interventions: Biological: Recombinant coagulation factor (rFVIIIFc) rFVI |
Recruiting |
Study Name: Alphanate in Immune Tolerance Induction Therapy Condition: Hemophilia A, Congenital Date: 2017-03-23 Interventions: Biological: Alphanate Daily intravenous infusion of Alphanate 100 IU/kg/day |
Not yet recruiting |
Study Name: Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients Condition: Antithrombin Deficiency Type 2 Date: 2017-03-21 Interventions: Drug: ATryn continuous infusion replenish serum thrombin levels |
Not yet recruiting |
Study Name: A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment Condition: Hemophilia A Date: 2017-03-10 Interventions: Biological: rFVIIIFc rFVIIIFc 200 IU/kg/day in ITI Period and 50 or 100 IU/kg (adjusted according to Inv |
Recruiting |
Study Name: Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency Condition: Factor VII Deficiency Date: 2017-03-04 Interventions: Biological: Eptacog alfa, biosimilar and reference medicinal product Novosev |
Not yet recruiting |
Study Name: Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A Condition: Hemophilia A Date: 2017-02-15 Interventions: Biological: SB-525 Single dose of investigational product SB-525 |
Recruiting |
Study Name: Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast. Condition: Haemophilia Developing Countries Date: 2017-02-13 Interventions: Other: Education Education of |